Compare Gilead Sciences, Inc. (GILD) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Taskus Inc — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Taskus Inc trades at $8.14 (market cap $723.41M). The key difference: Gilead Sciences, Inc. is far larger — about 252.1× Taskus Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Taskus Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Taskus Inc for 34 Days on average.
| GILD | TASK | |
|---|---|---|
Market Cap | $182.40B | $723.41M |
Volume | 4,469,821 | 201,303 |
Sector | Health | Technology |
52-Week High | $155.80 | $14.69 |
52-Week Low | $116.74 | $4.57 |
Typical Hold Time | 111 Days | 34 Days |
Enterprise Value | $205.46B | $1.09B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
TaskUs trades at $8.14, up 3.17% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with revenue growth to $1.18B in 2025 and net income margin expanding to 8.75%. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.29 expected, though Q1 2026 missed estimates. Valuation metrics appear attractive with P/E of 6.8 and P/S of 0.6, suggesting potential undervaluation.
The stock presents a compelling value opportunity given its low valuation multiples and strong profitability metrics, though technical weakness and competitive pressures in AI services create near-term headwinds. Analyst consensus remains positive with a $9.33 price target representing 15% upside potential from current levels, supported by institutional accumulation including Dimensional Fund Advisors' 12.8% position increase in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
